Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 15,189.21% | 12,385.07% | 12,969.75% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15,189.21% | 12,385.07% | 12,969.75% | -- | -- |
| Cost of Revenue | 943.37% | 817.58% | 1,430.15% | -- | -- |
| Gross Profit | 824.98% | 583.91% | 85.54% | -- | -- |
| SG&A Expenses | 42.14% | 46.69% | 80.45% | 11.63% | 13.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.65% | 24.23% | 20.57% | 6.84% | 13.74% |
| Operating Income | 28.60% | 24.75% | 7.42% | -6.19% | -13.29% |
| Income Before Tax | 34.82% | 26.04% | 7.89% | -6.53% | -12.17% |
| Income Tax Expenses | 188.57% | -22.28% | -205.66% | -- | -- |
| Earnings from Continuing Operations | 32.50% | 26.56% | 8.85% | -5.22% | -10.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.50% | 26.56% | 8.85% | -5.22% | -10.50% |
| EBIT | 28.60% | 24.75% | 7.42% | -6.19% | -13.29% |
| EBITDA | 31.77% | 27.76% | 11.19% | -1.87% | -9.76% |
| EPS Basic | 43.33% | 40.47% | 28.17% | 15.53% | 28.86% |
| Normalized Basic EPS | 44.14% | 40.05% | 27.39% | 13.54% | 27.19% |
| EPS Diluted | 43.33% | 40.47% | 28.17% | 15.53% | 28.86% |
| Normalized Diluted EPS | 44.14% | 40.05% | 27.39% | 13.54% | 27.19% |
| Average Basic Shares Outstanding | 19.12% | 23.37% | 26.88% | 24.58% | 55.34% |
| Average Diluted Shares Outstanding | 19.12% | 23.37% | 26.88% | 24.58% | 55.34% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |